Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at undersøge effektiviteten og sikkerheden af ​​anifrolumab hos voksne med kronisk og/eller subakut kutan lupus erythematosus (LAVENDER)

10. november 2026 opdateret af: AstraZeneca

Et multicenter, randomiseret, dobbeltblindt, placebokontrolleret, fase III-studie for at evaluere effektiviteten og sikkerheden af ​​anifrolumab hos voksne med kronisk og/eller subakut kutan lupus erythematosus, som er refraktære og/eller intolerante over for antimalariaterapi

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

339

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Ciudad de Buenos Aires, Argentina, 1221
        • Research Site
      • Córdoba, Argentina, 5000
        • Research Site
      • Córdoba, Argentina, X5004BAL
        • Research Site
      • Quilmes, Argentina, 1878
        • Research Site
      • San Miguel, Argentina, 1663
        • Research Site
      • Kogarah, Australien, 3168
        • Research Site
      • Melbourne, Australien, 3004
        • Research Site
      • Mitcham, Australien, 3132
        • Research Site
      • Westmead, Australien, 2145
        • Research Site
      • Woolloongabba, Australien, 04102
        • Research Site
      • Belo Horizonte, Brasilien, 30150-221
        • Research Site
      • Porto Alegre, Brasilien, 90035903
        • Research Site
      • Rio de Janeiro, Brasilien, 22470-220
        • Research Site
      • Salvador, Brasilien, 40150-150
        • Research Site
      • São Paulo, Brasilien, 05403-000
        • Research Site
      • Sofia, Bulgarien, 1784
        • Research Site
      • Sofia, Bulgarien, 1463
        • Research Site
      • Sofia, Bulgarien, 1528
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Research Site
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • Research Site
      • Toronto, Ontario, Canada, M5T 2S8
        • Research Site
      • Osorno, Chile, 200025
        • Research Site
      • Santiago, Chile, 7500571
        • Research Site
      • Santiago, Chile, 130021
        • Research Site
      • Barranquilla, Colombia, 080020
        • Research Site
      • Bogotá, Colombia, 110221
        • Research Site
      • Aarhus, Danmark, 641-8510
        • Research Site
      • Copenhagen, Danmark, 2100
        • Research Site
      • Cambridge, Det Forenede Kongerige, CB2 0QQ
        • Research Site
      • Leeds, Det Forenede Kongerige, LS2 9JT
        • Research Site
      • London, Det Forenede Kongerige, NW1 2PG
        • Research Site
      • London, Det Forenede Kongerige, SE5 9RS
        • Research Site
      • London, Det Forenede Kongerige, SE1 7EH
        • Research Site
      • London, Det Forenede Kongerige, NW3 2QG
        • Research Site
      • Newcastle upon Tyne, Det Forenede Kongerige, NE1 4LP
        • Research Site
      • Iloilo City, Filippinerne, 5000
        • Research Site
      • Lipa, Filippinerne, 4217
        • Research Site
      • Manila, Filippinerne, 1000
        • Research Site
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85028
        • Research Site
    • California
      • Covina, California, Forenede Stater, 91722
        • Research Site
      • La Jolla, California, Forenede Stater, 92037
        • Research Site
      • Los Angeles, California, Forenede Stater, 90045
        • Research Site
      • Los Angeles, California, Forenede Stater, 90089
        • Research Site
      • Orange, California, Forenede Stater, 92868
        • Research Site
      • San Francisco, California, Forenede Stater, 94143
        • Research Site
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06519
        • Research Site
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20037
        • Research Site
    • Florida
      • Fort Lauderdale, Florida, Forenede Stater, 33309
        • Research Site
      • Miami, Florida, Forenede Stater, 33174
        • Research Site
      • Plantation, Florida, Forenede Stater, 33324
        • Research Site
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • Research Site
      • Chicago, Illinois, Forenede Stater, 60611
        • Research Site
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Research Site
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Research Site
      • Boston, Massachusetts, Forenede Stater, 02115-5817
        • Research Site
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Research Site
      • Bloomfield Hills, Michigan, Forenede Stater, 48302
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Research Site
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68198-5885
        • Research Site
    • New York
      • New York, New York, Forenede Stater, 10028
        • Research Site
      • Rochester, New York, Forenede Stater, 14642
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28207
        • Research Site
      • Statesville, North Carolina, Forenede Stater, 28625
        • Research Site
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195
        • Research Site
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02903
        • Research Site
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Research Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75390-8843
        • Research Site
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22903
        • Research Site
      • Roanoke, Virginia, Forenede Stater, 24016
        • Research Site
      • Bois-Guillaume, Frankrig, 76031
        • Research Site
      • Dijon, Frankrig, 21000
        • Research Site
      • Lyon, Frankrig, 69437
        • Research Site
      • Montivilliers, Frankrig, 76290
        • Research Site
      • Nantes, Frankrig, 44000
        • Research Site
      • Paris, Frankrig, 75010
        • Research Site
      • Paris, Frankrig, 75014
        • Research Site
      • Paris, Frankrig, 75013
        • Research Site
      • Paris, Frankrig, 75970
        • Research Site
      • Poitiers, Frankrig, 86000, FR
        • Research Site
      • Toulouse, Frankrig, 31059
        • Research Site
      • Athens, Grækenland, 12462
        • Research Site
      • Athens, Grækenland, 16121
        • Research Site
      • Breda, Holland, 4818 CK
        • Research Site
      • Rotterdam, Holland, 3015 GD
        • Research Site
      • Brescia, Italien, 25123
        • Research Site
      • Cona, Italien, 44124
        • Research Site
      • Florence, Italien, 50121
        • Research Site
      • Milan, Italien, 20132
        • Research Site
      • Naples, Italien, 80138
        • Research Site
      • Reggio Emilia, Italien, 42123
        • Research Site
      • Roma, Italien, 00144
        • Research Site
      • Rome, Italien, 00168
        • Research Site
      • Chūōku, Japan, 104-8560
        • Research Site
      • Fukuoka, Japan, 812-8582
        • Research Site
      • Kanazawa, Japan, 920-8641
        • Research Site
      • Kita-gun, Japan, 761-0793
        • Research Site
      • Nagoya, Japan, 457-8510
        • Research Site
      • Nagoya, Japan, 467-8602
        • Research Site
      • Wakayama, Japan, 641-8510
        • Research Site
      • Yokohama, Japan, 232-0024
        • Research Site
      • tabashi City, Japan, 173-8606
        • Research Site
      • Changchun, Kina, 130021
        • Research Site
      • Changsha, Kina, 410011
        • Research Site
      • Chengdu, Kina, 610021
        • Research Site
      • Chongqing, Kina, 400016
        • Research Site
      • Dongguan, Kina, 523059
        • Research Site
      • Guangzhou, Kina, 510120
        • Research Site
      • Heilongjiang, Kina, 150086
        • Research Site
      • Jinan, Kina, 250022
        • Research Site
      • Shanghai, Kina, 200025
        • Research Site
      • Shanghai, Kina, 200443
        • Research Site
      • Shenzhen, Kina, 518053
        • Research Site
      • Shenzhen, Kina, 518020
        • Research Site
      • Shenzhen, Kina, 518052
        • Research Site
      • Zhuzhou, Kina, 412007
        • Research Site
      • Ürümqi, Kina, CN-830004
        • Research Site
      • Guadalajara, Mexico, 44340
        • Research Site
      • Guadalajara, Mexico, 44610
        • Research Site
      • Mexico City, Mexico, 07760
        • Research Site
      • Veracruz, Mexico, 91910
        • Research Site
      • Papatoetoe, New Zealand, 2025
        • Research Site
      • Katowice, Polen, 40-851
        • Research Site
      • Kielce, Polen, 25-316
        • Research Site
      • Ossy, Polen, 40-027
        • Research Site
      • Rzeszów, Polen, 35-055
        • Research Site
      • Warsaw, Polen, 02-637
        • Research Site
      • Braga, Portugal, 4710-243
        • Research Site
      • Lisbon, Portugal, 1649-035
        • Research Site
      • Porto, Portugal, 4099-001
        • Research Site
      • Bucharest, Rumænien, 020125
        • Research Site
      • Iași, Rumænien, 700291
        • Research Site
      • Belgrade, Serbien, 11000
        • Research Site
      • Kragujevac, Serbien, 34000
        • Research Site
      • Košice, Slovakiet, 04001
        • Research Site
      • Piešťany, Slovakiet, 92101
        • Research Site
      • Barcelona, Spanien, 8035
        • Research Site
      • Barcelona, Spanien, 08025
        • Research Site
      • Castellon, Spanien, 12004
        • Research Site
      • Granada, Spanien, 18012
        • Research Site
      • L'Hospitalet de Llobregat, Spanien, 08907
        • Research Site
      • Las Palmas de Gran Canaria, Spanien, 35010
        • Research Site
      • Madrid, Spanien, 28034
        • Research Site
      • Madrid, Spanien, 28041
        • Research Site
      • Madrid, Spanien, 28040
        • Research Site
      • Madrid, Spanien, 28006
        • Research Site
      • Majadahonda, Spanien, 28222
        • Research Site
      • Salamanca, Spanien, 37007
        • Research Site
      • Seville, Spanien, 41014
        • Research Site
      • Valencia, Spanien, 46014
        • Research Site
      • Valencia, Spanien, 46017
        • Research Site
      • Vigo, Spanien, 36200
        • Research Site
      • Cape Town, Sydafrika, 7500
        • Research Site
      • Johannesburg, Sydafrika, 2193
        • Research Site
      • Seoul, Sydkorea, 03080
        • Research Site
      • Seoul, Sydkorea, 06591
        • Research Site
      • Seoul, Sydkorea, 06973
        • Research Site
      • Kaohsiung City, Taiwan, 83301
        • Research Site
      • Taichung, Taiwan, 404
        • Research Site
      • Taipei, Taiwan, 10449
        • Research Site
      • Bangkok, Thailand, 10330
        • Research Site
      • Bangkok, Thailand, 10700
        • Research Site
      • Hat Yai, Thailand, 90110
        • Research Site
      • Khlong Luang, Thailand, 12120
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Research Site
      • Cordaleo, Tyrkiet (Türkiye), 35575
        • Research Site
      • Istanbul, Tyrkiet (Türkiye), 34098
        • Research Site
      • Kayseri, Tyrkiet (Türkiye), 38039
        • Research Site
      • Samsun, Tyrkiet (Türkiye), 55270
        • Research Site
      • Berlin, Tyskland, 10117
        • Research Site
      • Bochum, Tyskland, 44791
        • Research Site
      • Dresden, Tyskland, 01307
        • Research Site
      • Erlangen, Tyskland, 91054
        • Research Site
      • Essen, Tyskland, 45147
        • Research Site
      • Freiburg im Breisgau, Tyskland, 79104
        • Research Site
      • Hanover, Tyskland, 30625
        • Research Site
      • Kiel, Tyskland, 24105
        • Research Site
      • Leipzig, Tyskland, 04103
        • Research Site
      • Mainz, Tyskland, 55131
        • Research Site
      • Marburg, Tyskland, 35043
        • Research Site
      • Regensburg, Tyskland, 93053
        • Research Site
      • Wuppertal, Tyskland, 42283
        • Research Site
      • Graz, Østrig, 8036
        • Research Site
      • Innsbruck, Østrig, 6020
        • Research Site
      • Linz, Østrig, 4020
        • Research Site
      • Vienna, Østrig, 1130
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key inclusion criteria:

  • Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:

    • CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
    • Inadequate response or intolerant to antimalarial therapy.
  • Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.

  • Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Key exclusion criteria:

  • History or evidence of suicidal ideation.
  • Severe or life-threatening Systemic lupus erythematosus (SLE).
  • Active SLE or Sjögren's Syndrome.
  • Any active skin conditions other than CLE that may interfere with the study.
  • History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
  • History of recurrent infection requiring hospitalization and IV antibiotics.
  • COVID-19 infection.
  • Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
  • At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Anifrolumab

Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51.

Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Placebo komparator: Placebo

Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.

Matching placebo solution for injection in aPFS.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Tidsramme: At Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from baseline in total CLASI-A score
Tidsramme: At Week 24

The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE.

At Week 24
Number of participants with CLASI-70 response
Tidsramme: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 12
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Tidsramme: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients.

At Week 12
Number of participants with CLASI-50 response
Tidsramme: At Week 12 and Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder.

At Week 12 and Week 24
Number of participants who are sustained CLASI-70 responders
Tidsramme: Up to Week 52

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated.

Up to Week 52
Serum trough (pre-dose) concentrations of anifrolumab
Tidsramme: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)

The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
Number of participants with positive antidrug antibody
Tidsramme: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)

The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
Percent change from baseline in suppression of the Interferon 21-gene
Tidsramme: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)

The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
Change from baseline in Skindex-29+3 Symptom domain scores
Tidsramme: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life.

At Week 24
Change from baseline in Skindex-29+3 Emotion domain scores
Tidsramme: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Function domain scores
Tidsramme: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Tidsramme: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Total score
Tidsramme: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Time from IP start date to CLASI-70 response.
Tidsramme: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24
Time from IP start date to CLASI-50 response.
Tidsramme: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with adverse events
Tidsramme: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE.

Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. juni 2024

Primær færdiggørelse (Faktiske)

2. november 2026

Studieafslutning (Anslået)

10. august 2027

Datoer for studieregistrering

Først indsendt

1. august 2023

Først indsendt, der opfyldte QC-kriterier

22. august 2023

Først opslået (Faktiske)

29. august 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • D346BC00001
  • 2021-003698-70 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingsadgangskriterier

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .